Changes in Ovarian Function after Radioactive Iodine among Patients with Differentiated Thyroid Carcinoma at St. Luke's Medical Center, Philippines

  • Michael D. Rosario Section of Endocrinology, Diabetes & Metabolism, St. Luke’s Medical Center, Philippines
  • Gabriel V. Jasul, Jr. Section of Endocrinology, Diabetes & Metabolism, St. Luke’s Medical Center, Philippines Section of Endocrinology, University of the Philippines-Philippine General Hospital

Abstract

Objective. To determine the prevalence of menstrual and reproductive dysfunction among subjects who have undergone radioiodine treatment for thyroid carcinoma. 

 

Methodology. This study enrolled adult women with Differentiated Thyroid Carcinoma who received the treatment at age 40 years and below.  Data was processed using SAS program and evaluated using Fischer’s test and Wilcoxon test.

 

Results. The study enrolled 46 women.  Three reported cycle irregularities, 4 reported changes in amount of bleeding and 1 had amenorrhea.  The prevalence rate of menstrual abnormalities was 15.2%.  These women received a significantly higher dose of radioactive iodine (RAI) (120 vs. 110 mCi, p = 0.0064).

 

Eleven women tried to conceive and there were 5 births to 5 different subjects after radiation. There were no congenital anomalies and 1 miscarriage.  Four women were menopausal with an average age of 44.4 years old. 

 

Conclusion. This study showed that the prevalence of menstrual disturbances after high dose radioactive iodine treatment among thyroid cancer patients is 15.2%.  The affected group received a significantly higher dose of radioactive iodine compared to the unaffected group.

Downloads

Download data is not yet available.

References

Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 2002; 78:92-93

Sioka C, Kouraklis G, Zafirakis A, Manetou A, Dimakopoulos N. Menstrual cycle disorders after therapy with iodine-131. Fertil Steril. September 2006; 86(3):625-629

Raymond JP, Izembart M, Marliac V, Dagousset F, Merceron RE, Vulpillat M. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J. Clin. Endocrinol. Metab. 1989; 69:186-190.

Kronenberg H. Williams Textbook of Endocrinology 11th edtion. Saunders Elsevier, 2008

Gardner D. Greenspan’s Basic and Clinical Endocrinology 8th edition. McGraw-Hill Companies, 2007

Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F. 131 I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: Results of a retrospective study. J. Clin. Endocrinol. Metab. 2001; 86:3512-3515

Souza R, Alvarenga F, Villas-Boas F, et al. Radioiodine therapy and age at menopause in patients with thyroid cancer. Clinical Endocrinology. 2006; 64:225-226.

García-Quirós M, Muñoz J, Hernández M, Torres C. Age of menopause in patients with differentiated thyroid cancer treated with radioiodine. Endocrinol Nutr. March 2010; 57(3):105-109.

Garsi J., Schlumberger M., Rubino C. et al. Therapeutic administration of 131 I for differentiated thyroid cancer: Radiation to ovaries and outcome of pregnancies. J Nucl Med. May 2008; 49(5):845-852.

Published
2014-05-21
How to Cite
Rosario, M. D., & Jasul, Jr., G. V. (2014). Changes in Ovarian Function after Radioactive Iodine among Patients with Differentiated Thyroid Carcinoma at St. Luke’s Medical Center, Philippines. Journal of the ASEAN Federation of Endocrine Societies, 27(1), 63. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/14
Section
Original Articles